866-997-4948(US-Canada Toll Free)

Stomach Cancer - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Oct 2010

Category :

Cancer

No. of Pages : 71 Pages



GlobalDatas report, Stomach Cancer Pipeline Assessment and Market Forecasts to 2017, is an essential source of information and analysis on the global stomach cancer market. The report identifies the key trends shaping and driving the global stomach cancer market. The report also provides insights into the prevalent competitive landscape and the emerging players expected to alter the market position of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products in the global stomach cancer segment. 
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

GlobalDatas analysis suggests that the global gastric cancer market was worth $750m in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.3% to $1,422m in 2017. Most of the chemotherapies are already off-patent while Taxotere and Xeloda are expected to lose their patents during 2010 to 2011. Taxoteres generic version, produced by Hospira, has already been approved in Europe through the decentralized procedure. The market is expected to be driven by the increase in demand due to the launch of promising targeted therapies currently in the late stage of development. The pending approval of Herceptin in the US and Japan will also boost the revenues generated in the stomach cancer market. However, the new therapies are not expected go off-patent before 2017. Therefore, the market is expected to witness strong growth in market revenues in the forecast period.

Scope

The scope of the report includes: 

  • Annualized global stomach cancer market revenues data from 2001 to 2009, forecast for eight years to 2017. 
  • Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan. 
  • Pipeline analysis data split across different phases by mechanism of action and emerging trends. The key classes of mechanism of action are mTOR inhibitors, PARP inhibitors, microtubule inhibitors, VEGFR inhibitors, multiple tyrosine kinase inhibitors, Heat Shock Protein 90 inhibitors, Eg5 inhibitors, Farnesyl-OH-transferase inhibitors, angiogenesis inhibitors and combinations of several existing chemotherapies. 
  • Analysis of the current and future competition in the global stomach cancer market. The key market players covered include GlaxoSmithKline, Novartis Pharmaceuticals, Merck & Co, Eli Lilly and Company, Amgen, Hoffmann-La Roche and Pfizer Inc.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the future stomach cancer market
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most promising product candidates in the pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global stomach cancer market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global stomach cancer market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the maximum opportunities for consolidation, investments and strategic partnerships.
  • Whats the next big thing in the global stomach cancer market landscape? Identify, understand and capitalize.
Table Of Content

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5

2 Stomach Cancer Introduction 6
2.1 GlobalData Pipeline Report Guidance 7

3 Stomach Cancer: Market Characterization 8
3.1 Overview 8
3.2 Stomach Cancer Market Size 8
3.3 Stomach Cancer Market Forecast and CAGR 10
3.4 Drivers and Barriers for the Stomach Cancer Market 11
3.4.1 Drivers for the Stomach Cancer Market 11
3.4.2 Barriers for the Stomach Cancer Market 11
3.5 Opportunity and Unmet Need 11
3.6 Key Takeaway 13

4 Stomach Cancer Market: Competitive Assessment 14
4.1 Overview 14
4.2 Strategic Competitor Assessment 14
4.3 Product Profiles of Major Marketed Drugs in the Stomach Cancer Market 15
4.3.1 Herceptin (trastuzumab) 15
4.3.2 Taxotere (docetaxel) 17
4.3.3 Xeloda 18
4.3.4 Gleevec (imatinib) 19
4.4 Key Takeaway 21

5 Stomach Cancer Market: Pipeline Assessment 22
5.1 Overview 22
5.2 Strategic Pipeline Assessment 23
5.2.1 Technology Trends Analytic Framework 23
5.3 Stomach Cancer Promising Drugs Under Clinical Development 25
5.4 Molecule Profile for Promising Drugs Under Clinical Development 26
5.4.1 Tykerb (Lapatinib) 26
5.4.2 Afinitor (Everolimus) 26
5.4.3 IMC-1121B (ramucirumab) 27
5.4.4 Cetuximab plus capecitabine and cisplatin 28
5.4.5 Apatinib (YN968DI) 28
5.5 Stomach Cancer Market Clinical Pipeline by Mechanism of Action 29
5.6 Stomach Cancer Market Pipeline by Clinical Phase of Development 30
5.6.1 Stomach Cancer Market Phase III Clinical Pipeline 31
5.6.2 Stomach Cancer Market Phase II Clinical Pipeline 33
5.6.3 Stomach Cancer Market Phase I Clinical Pipeline 44
5.6.4 Stomach Cancer Market Pre-Clinical Pipeline 47
5.6.5 Stomach Cancer Market Filed Molecules Pipeline 47
5.7 Key Takeaway 47

6 Stomach Cancer: Implications for Future Market Competition 48

7 Stomach Cancer Market: Future Players in the Stomach Cancer Market 50
7.1 Introduction 50
7.2 GlaxoSmithKline 51
7.2.1 Company Overview 51
7.2.2 Financial Performance 51
7.2.3 Business Description 51
7.3 Novartis AG 52
7.3.1 Company Overview 52
7.3.2 Financial Performance 52
7.3.3 Business Description 53
7.4 Eli Lilly and Company 54
7.4.1 Company Overview 54
7.4.2 Financial Performance 54
7.4.3 Business Description 54
7.5 Merck & Co 56
7.5.1 Company Overview 56
7.5.2 Financial Performance 56
7.5.3 Business Description 56
7.6 Amgen 58
7.6.1 Company Overview 58
7.6.2 Financial Performance 58
7.6.3 Business Description 58
7.7 Hoffmann-La Roche Ltd. 60
7.7.1 Company Overview 60
7.7.2 Financial Performance 60
7.7.3 Business Description 60
7.8 Pfizer 62
7.8.1 Company Overview 62
7.8.2 Financial Performance 62
7.8.3 Business Description 62

8 Stomach Cancer Market: Appendix 65
8.1 Definitions 65
8.2 Acronyms 65
8.3 Research Methodology 67
8.3.1 Coverage 67
8.3.2 Secondary Research 68
8.3.3 Forecasting 68
8.3.4 Primary Research 69
8.3.5 Expert Panels 70
8.4 Contact Us 70
8.5 Disclaimer 70
8.6 Sources 71

List of Table


Table 1: Stomach Cancer Therapeutic Market Forecast ($m), 20012009 9
Table 2: Stomach Cancer Therapeutic Market Forecast ($m), 20092017 10
Table 3: Major Marketed Products Comparison in Stomach Cancer Therapeutic Market, 2010 20
Table 4: Stomach Cancer Most Promising Drugs under Clinical Development, 2010 25
Table 5: Stomach Cancer Phase III Clinical Pipeline, 2010 31
Table 6: Stomach Cancer Phase II Clinical Pipeline, 2010 33
Table 7: Stomach Cancer Phase I Clinical Pipeline, 2010 44
Table 8: Stomach Cancer Pre-clinical Pipeline, 2010 47
Table 9: Stomach Cancer Filed Molecules Pipeline, 2010 47
Table 10: GlaxoSmithKline Clinical Pipeline for Stomach Cancer, 2010 52
Table 11: Novartis AG Clinical Pipeline for Stomach Cancer, 2010 54
Table 12: Eli Lilly and Company Clinical Pipeline for Stomach Cancer, 2010 56
Table 13: Merck & Co - Clinical Pipeline for Stomach Cancer, 2010 58
Table 14: Amgen - Clinical Pipeline for Stomach Cancer, 2010 59
Table 15: Hoffmann-La Roche - Clinical Pipeline for Stomach Cancer, 2010 62
Table 16: Pfizer - Clinical Pipeline for Stomach Cancer, 2010 64

List of Chart


Figure 1: Stomach Cancer Therapeutic Market Historical Revenues ($m), 2001-2009 9
Figure 2: Stomach CancerTherapeutic Market Forecasts ($m), 2009-2016 10
Figure 3: Opportunity and Unmet Need in the Stomach Cancer Therapeutic Market, 2010 13
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Stomach Cancer Therapeutic Market, 2010 15
Figure 5: Technology Trends Analytic Framework Stomach CancerTherapeutic Market, 2010 23
Figure 6: Technology Trends Analytic Framework of the Stomach Cancer Pipeline Description, 2010 24
Figure 7: Stomach Cancer Therapeutic Market Clinical Pipeline by Mechanism of Action, 2010 29
Figure 8: Stomach Cancer Pipeline by Phase of Clinical Development, 2010 30
Figure 9: Implications for Future Market Competition in Stomach Cancer, 2010 48
Figure 10: Stomach Cancer Therapeutic Market Clinical Pipeline by Company, 2010 50

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *